Oramed Pharmaceuticals (ORMP) Research & Development (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Research & Development came in at $1.6 million in Q1 2026, down 27.74% YoY from $2.2 million in Q1 2025, and down 19.82% on a QoQ basis from $2.0 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Research & Development (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 15 years of Research & Development data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Research & Development fell 27.74% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (down 21.52% YoY) and the FY2025 annual result came in at $6.4 million, up 0.9% from the prior year.
- Research & Development fell to $1.6 million in Q1 2026, from $2.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $9.0 million in Q4 2022 to a low of $380000.0 in Q2 2022.
- A 5-year average of $2.3 million and a median of $1.6 million in 2026 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 379.21% in 2023, down 80.46% in 2023.
- Tracing ORMP's Research & Development over 5 years: stood at $9.0 million in 2022, then plunged by 80.46% to $1.8 million in 2023, then decreased by 17.27% to $1.5 million in 2024, then surged by 36.07% to $2.0 million in 2025, then dropped by 19.82% to $1.6 million in 2026.
- The last three Research & Development figures came in at $1.6 million (Q1 2026), $2.0 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Oramed Pharmaceuticals | 196.17 Mn | 196.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.59 Mn |
| Dec 31, 2025 | 1.99 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 1.77 Mn |
| Sep 30, 2023 | 957,000.00 |
| Jun 30, 2023 | 1.82 Mn |
| Mar 31, 2023 | 4.43 Mn |
| Dec 31, 2022 | 9.04 Mn |
| Sep 30, 2022 | 463,000.00 |
| Jun 30, 2022 | 380,000.00 |
| Mar 31, 2022 | 5.84 Mn |
| Aug 31, 2021 | 20.99 Mn |
| Nov 30, 2019 | 2.02 Mn |
| Aug 31, 2019 | 2.20 Mn |